This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Rho-associated coiled-coil containing protein kinase 1 (ROCK1); ROCK2	<p><i>In vitro</i> and mouse studies identified an inhibitor of ROCK1 and ROCK2 that could help treat breast cancer. <i>In vitro</i>, a pyridylthiazole-based compound inhibited ROCK1 with an IC₅₀ value of 14.5 nM and ROCK2 with an IC₅₀ value of 6.2 nM. In human breast cancer cell lines, the inhibitor decreased migration, invasion and anchorage-independent growth compared with vehicle. In a mouse xenograft model of human breast cancer, the inhibitor decreased tumor growth compared with vehicle. Next steps include additional preclinical testing prior to an IND submission.</p> <p>Kadmon Corp. LLC's ROCK2 inhibitor, KD025, is in Phase I testing to treat inflammation and is in preclinical testing to treat cancer.</p> <p>SciBX 5(33); doi:10.1038/scibx.2012.862 Published online Aug. 23, 2012</p>	Patent application filed; available for licensing	<p>Patel, R.A. <i>et al. Cancer Res.</i>; published online July 30, 2012; doi:10.1158/0008-5472.CAN-12-0954</p> <p>Contact: Said M. Sebti, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla. e-mail: said.sebti@moffitt.org</p>